Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma

Advances in Therapy
Kenichi Ishizawa, Tomoko Yanai

Abstract

Brentuximab vedotin (BV) is an antibody-drug conjugate that has demonstrated effectiveness as a monotherapy for patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma via several clinical trials. Salvage chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplantation (HSCT) has been performed as a second- or later-line regimen for improving the survival of patients with lymphoma. In particular, the effectiveness of autologous HSCT and the importance of achieving a complete response prior to autologous HSCT are established in Hodgkin lymphoma. Several clinical trials have reported that salvage chemotherapy followed by autologous HSCT showed high response rates, although significant treatment-related hematological toxicity was observed. In the present article, we review clinical reports for assessing the efficacy and safety of relatively less toxic BV as a bridging therapy before HSCT or as a consolidation therapy post-HSCT in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma. Generally, the reported BV regimens seem to be effective and well tolerated in such patients, and no significant influence of BV treatment is...Continue Reading

References

Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G AkpekR J Jones
Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A JostingUNKNOWN Participating Centers
Jun 13, 2003·The New England Journal of Medicine·Volker DiehlUNKNOWN German Hodgkin's Lymphoma Study Group
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
May 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara ProAndrei Shustov
May 6, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Manuel AfableUday Popat
Jul 28, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert ChenStephen J Forman
Aug 16, 2016·Blood·Ramón García-Sanz
Dec 12, 2017·The New England Journal of Medicine·Joseph M ConnorsUNKNOWN ECHELON-1 Study Group
Apr 11, 2018·American Journal of Hematology·Stephen M Ansell
Jan 19, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Garcia-SanzC Martinez
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Garcia-SanzC Martinez

❮ Previous
Next ❯

Citations

Mar 11, 2021·Asia-Pacific Journal of Oncology Nursing·Gholamreza Bahoush

❮ Previous
Next ❯

Methods Mentioned

BETA
ICE

Related Concepts

Related Feeds

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.